AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03515148 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vibration and eccentric exercise
Description: 12 weeks, 5 days/week, once a day, 2 exercise, 3 sets/execise, 15 repetition/set of eccentric exercise of foot plantar flexors First exercise with knee in extension, second exercise with knee in flexion.During the exercise subjects will be subjected to vibration. Vibrations parameters: Frequency: 35Hz, Amplitude: 4 milimeters, Force: 3,9G
Study NCT02822794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg tablet administered orally once daily
Study NCT02822794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Capsules administered orally in a divided daily dose according to package insert weight-based dosing recommendations (≤ 60 kg = 600 mg, > 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)
Study NCT00537524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 Influenza Vaccine
Description: Two 0.5mL injections of H5N1 influenza vaccine containing 7.5μg of H5N1 antigen (A/Vietnam/1194/2004), administered 3 weeks apart, and one 0.5mL injection of H5N1 vaccine 12 months after the second dose, IM into the deltoid muscle (preferably of the non-dominant arm) or anterolateral thigh (depending on the muscle mass).
Study NCT00537524 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H5N1 Influenza Vaccine
Description: Two 0.25mL or 0.5mL injections of H5N1 influenza vaccine, administered 3 weeks apart, IM into the deltoid muscle (preferably of the non-dominant arm) or anterolateral thigh (depending on the muscle mass).
Study NCT04590391 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Visual and Auditory Breathing-swallowing Coordinated Training device
Description: This device has a structure in which a band wrapped around the chest detects the respiratory phase from changes in the lung volume, and the connected device lights a signal and sounds a sound.
Study NCT04010110 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: visual field testing (10-2), spectral domain ocular coherence tomography and Fundus auto-fluorescence
Description: The diagnosis of toxic retinopathy was based on the positivity of at least two objective tests to confirm the subjective findings. The presence or absence of toxicity was recorded.
Study NCT00637169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Titration of oxygen therapy
Description: Supplemental oxygen to maintain functional arterial oxygen saturations in one of two saturation target ranges.
Study NCT00637169 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Titration of oxygen therapy
Description: Supplemental oxygen to maintain functional arterial oxygen saturations in one of two saturation target ranges.
Study NCT03624361 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glaucoma device implantation in a stand-alone procedure
Description: MINIject implant is used to reduce intra-ocular pressure in the eye through a minimally-invasive Glaucoma surgical intervention.~The intervention is to be performed as stand-alone surgery.
Study NCT01459796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilonacept
Description: Rilonacept 160 mg loading dose followed by Rilonacept 80 mg/2 mL injections qw for 52 weeks.
Study NCT01459796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo loading dose followed by placebo injections (2 mL) qw for 52 weeks.
Study NCT01459796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Allopurinol 50 or 100 mg, orally daily for 52 weeks as background treatment.
Study NCT03036514 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sublingual sufentanil tablet system
Description: Usage of a new patient-controlled SSTS in the postoperative phase after laminectomy or spinal fusion.
Study NCT03036514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patient-controlled intravenous analgesia
Description: Usage of classically used patient-controlled intravenous mophine-based postoperative analgesia after laminectomy or spinal fusion.
Study NCT01813604 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Group A: Trivalent Oral Polio Vaccine
Description: Group A will receive 3 doses of trivalent oral polio vaccine (tOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
Study NCT01813604 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Group B: Bivalent Oral Polio Vaccine
Description: Group B will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
Study NCT01813604 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Group C: Inactivated Polio Vaccine
Description: Group C will receive 2 doses of inactivated polio vaccine (IPV) at 6 and 14 weeks of age. IPV will be administered intramuscularly using standard needle and syringe. A challenge dose of tOPV will be administered at 18 weeks of age.
Study NCT01813604 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Group D: fractional IPV (f-IPV)
Description: Group D will receive 2 doses of fractional inactivated polio vaccine (f-IPV) at 6 and 14 weeks of age. f-IPV (one-fifth dose of IPV) will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
Study NCT01813604 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Arm E: f-IPV and bOPV
Description: Group E will receive 2 doses of f-IPV at 6 and 14 weeks of age with bOPV at 10 weeks of age. f-IPV will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
Study NCT06391996 — intervention group
Intervention type: DRUG
Intervention: After exclusion of relevant contraindications, participants received subcutaneous ustekinumab/secukinumab therapy.
Description: During the treatment period, participants received either ustekinumab at weeks 0, 4, 16, and every 12 weeks thereafter until week 48, or secukinumab at weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter until week 48. The dose of ustekinumab/secukinumab was referenced to the dose used for moderate to severe plaque psoriasis. The single dose of ustekinumab was 45 mg for adult subjects weighing ≤ 100 kg, and 90 mg for subjects weighing > 100 kg. The ustekinumab dosage for pediatric participants was 0.75 mg/kg for participants weighing \< 60 kg; 45 mg for pediatric participants weighing 60 kg to 100 kg; and 90 mg for pediatric participants weighing > 100 kg. The secukinumab dosage was 300mg for adult humans. Pediatric participants received a dose based on their weight category ( \<50 kg, ≥50 kg): participants weighing \< 50 kg received 75 mg, those weighing ≥ 50 kg received 150 mg.
Study NCT01268683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide for Injection
Description: Administered as specified in the treatment arm.
Study NCT03401762 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MCI
Description: EMG-controlled game
Study NCT03401762 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham MCI
Description: Sham control game
Study NCT00491790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Montelukast 4 mg rapid dissolving granules in sterile water given orally once
Study NCT02943980 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CMAC Videolaryngoscope
Description: In a randomised order we evaluate the quality of the IONM after securing the airway with the CMAC
Study NCT02943980 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macintosh Laryngoscope
Description: In a randomised order we evaluate the quality of the IONM after securing the airway with the conventional Macintosh Laryngoscope
Study NCT02426424 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Watchpat
Description: WatchPAT ™ is an FDA-approved portable diagnostic device that uses the most innovative technology to ensure the accurate screening, detection, and the follow-up treatment of sleep apnea.
Study NCT00991887 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy (XRT)
Description: The dose will be 700 gray (derived unit of ionizing radiation dose in the International System of Units) in a single fraction, using AP-PA fields calculated to midplane. No Less than 6 MV energy photons will be used, and no bolus is placed on the skin. The field covers the entire joint, the antecubital fossa and the olecranon process. A strip of skin at the antecubital area is generally shielded, but is not an absolute requirement for this study.
Study NCT03000010 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Incisional Wound Vac
Study NCT03000010 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Bandage
Study NCT00491790 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sterile water
Description: Sterile water
Study NCT03565406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mocetinostat Induction Phase + Ipilimumab + Nivolumab
Description: Treatment Cycle 1: Mocetinostat at a dose of 90 mg PO TIW; ipilimumab will be administered IV at a dose of 1 mg/kg and nivolumab will be administered IV at a dose of 3 mg/kg during the 12-week induction period. The induction phase will last for 2 treatment cycles.~Treatment Cycle 2: Mocetinostat at a dose of 70 mg PO TIW ipilimumab will be administered IV at a dose of 1 mg/kg and nivolumab will be administered IV at a dose of 3 mg/kg during the 12-week induction period. The induction phase will last for 2 treatment cycles.
Study NCT03565406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab
Description: De-escalation Phase 1: Mocetinostat will be administered 50 mg PO TIW during each 84-day treatment cycle. Ipilimumab will be administered IV at a dose of 1 mg/kg and nivolumab will be administered IV at a dose of 3 mg/kg~De-escalation Maintenance Phase 2: Mocetinostat will be administered 40 mg PO TIW during each 84-day treatment cycle. Ipilimumab will be administered IV at a dose of 0.3 mg/kg and nivolumab will be administered IV at a dose of 1 mg/kg during period
Study NCT03282084 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: EGD with biopsy
Description: Stop PPI and schedule for EGD with biopsy and Wireless pH capsule testing for 7-10 days later. Consider gastric emptying scan or high resolution esophageal manometry
Study NCT03282084 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: EGD and impedance-pH study on PPI
Description: Continue PPI and schedule EGD and Impedance-pH study on PPI. Consider gastric emptying scan or high resolution esophageal manometry
Study NCT01151241 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Elbow arthroscopy with infraclavicular nerve block and continuous local anesthetic infusion to day 3 post op.
Description: Patients undergoing elbow arthroscopy surgery will receive standard anesthesia/analgesia, including infraclavicular nerve block and general anesthesia for surgery followed by infraclavicular catheter infusion of local anesthetic until day 3 after surgery.
Study NCT01151241 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Elbow arthroscopy with infraclavicular nerve block and continuous local anesthetic infusion to day 3 post op.
Description: Patients undergoing elbow arthroscopy surgery will receive standard anesthesia/analgesia, including infraclavicular nerve block and general anesthesia for surgery followed by infraclavicular catheter infusion of local anesthetic until day 3 after surgery.
Study NCT01151241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Discharge
Description: Patients will be discharged home on the first day after surgery, with infraclavicular catheter infusion of local anesthetic in place.
Study NCT01151241 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Discharge
Description: Patients will remain in hospital and be discharged per current discharge criteria, once the infraclavicular catheter has been removed on day 3 post op. Typical discharge occurs on day 3 or 4 post op.
Study NCT02170727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCV/ASV/BMS-791325
Study NCT04166305 — intervention group
Intervention type: GENETIC
Intervention: Genetic study for SCN1A c.3184 A/G and CCL2-2518G>A polymorphism:
Description: DNA analysis: Genomic DNA will be extracted from EDTA-anticoagulated peripheral blood (QIAamp DNA Blood mini kit,QIAGEN).~Genotyping of SCN1A c.3184 A/G(rs2298771) polymorphism
Study NCT00821626 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BD Directigen EZ Flu A+B
Description: Naso-pharyngeal swab and rapid flu test
Study NCT00821626 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: No rapid flu test
Study NCT02554682 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sexual Health
Description: Psychoeducational workbook, worksheets, tip sheets, and health coaching session about sexual health, sexually transmitted disease (STD) prevention, and safe sex practices for teenager.
Study NCT02554682 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Alcohol Prevention
Description: Psychoeducational workbook, worksheets, tip sheets, and health coaching session about alcohol prevention and safety, underage drinking, and drinking and driving.
Study NCT02554682 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Teen Driving
Description: Psychoeducational workbook, worksheets, videos, tip sheets, and health coaching session about how parents can help supervise their teens' safe driving practices and how to talk with their teen about important safety topics for teen drivers.
Study NCT02841137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: comparison of different dosages of drug towards the active comparator
Study NCT02426424 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Continuous positive airway pressure (CPAP) is a form of positive airway pressure ventilator, which applies mild air pressure on a continuous basis to keep the airways continuously open in a patient who is able to breathe spontaneously on his or her own.
Study NCT00501111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3480
Description: 3 oral doses
Study NCT00501111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Study NCT00447499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatuline Autogel (lanreotide acetate)
Description: Injections
Study NCT00447499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home administration
Description: Questionnaire
Study NCT02332122 — intervention group
Intervention type: PROCEDURE
Intervention: Sputum induction
Description: Patients will have to puff 200µg of salbutamol (metered-dose inhaler with spacer device). After 10 minutes FEV1 will be measured with MIR spirobank. If FEV1 is >= 30% we can safely proceed with sputum induction. An ultrasonic nebulizer will be used to induce sputum. 4% sodiumchloride will be inhaled. Induction will be performed at 5-min intervals until a sample of good quality is obtained. Sodiumchloride of 5% will be used if no good sample is obtained after two intervals with the 4% solution. Maximal time of induction will be 20 minutes. Subjects will spit saliva into one container and rinse the mouth thoroughly with water before coughing sputum into another sterile container. Samples will be refrigerated at 4°C and processed within 24 hours of collection.
Study NCT02332122 — intervention group
Intervention type: PROCEDURE
Intervention: Skin prick test
Description: Skin Prick Test is a reliable method to diagnose IgE-mediated allergic disease. It is minimally invasive and results are immediately available. Interpretation utilizes the presence and degree of cutaneous reactivity as a surrogate marker for sensitization. A positive control, a negative control and Aspergillus fumigatus will be tested. Location will be Protocol version 1 3/11/2014 marked on the volar aspect of the forearm and drops of each solution will be placed (>= 2cm between drops). A single-head metal lancet will be pressed through the drop of allergen extract and held against the skin for at least 1 second. A new lancet will be utilized for each drop. A wheal diameter of >= 3mm is a positive result.
Study NCT02332122 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: MRC: Medical Research Council Scale CAT: COPD Assessment Test SGRQ: Saint George's respiratory questionnaire
Study NCT04260100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Care Self-Management Mobile Health Application
Description: In day 1, the participant will receive a Foot Care Kit consist of a mirror, a tube of lotion, a small towel, and a nail clipper. The participant will enrol in 3-hour workshop for general management of diabetes mellitus, diabetic foot care and dietary management. The participant will be invited to install Diabetes Care Self-Management Mobile Health Application. The mobile application is meant for sources of referral for diabetic foot care and dietary care, and for record purpose (diary) of any foot care activities carried out that participant needs to enter in the application during his/her home. The participant will be trained for the use of Diabetes Care Mobile Health Application. In addition, the participant will be invited to join a WhatsApp group for the medium of communication. The program will be lasting for 5 weeks.
Study NCT03980171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: A flat dose of 1000mg IV will be given every cycle during induction. a cycle is 28 days.During maintenance 1000mg IV will be given every second cycle for upto 2 years.
Study NCT03980171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: During dose escalation, the doses for venetoclax can be 400mg daily days 1-10, 800mg daily days 1-10, 400mg daily continuous or 800mg daily continuous. 6 cycles of treatment will be given during induction. Once the recommended phase 2 dose (RP2D) is established that dose will be used in dose expansion. A further 6 cycles of venetoclax will be given during maintenance if required based on response at the end of induction.
Study NCT03980171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: During dose escalation, the doses of lenalidomide can be 15mg for days 1-21 or 20mg for days 1-21. 6 cycles of treatment will be given during induction. During maintenance the dose of lenalidomide will be 10mg continuous for a further 6 cycles if required based on response at the end of induction.
Study NCT02630147 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vanilla scent
Description: A 12-hour continuous recording for monitoring hemoglobin oxygen saturation, electrocardiogram and respiratory movements will be performed while the infant is exposed to vanilla scent (from vanilla solution on the infant's pyjamas).
Study NCT05088733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yang Yin Fu Zheng Jie Du therapy
Description: Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.
Study NCT05088733 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine medical care
Description: Routine medical care
Study NCT05088733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine medical care
Description: Routine medical care
Study NCT03602547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM082 plus JS001
Description: CM082：200mg once a day (qd) orally (taken within half an hour after breakfast). JS001 :An intravenous infusion of a solution having a concentration of 1-10 mg/ml was prepared with 0.9% physiological saline, and administered once every two weeks. Using an inline filter (0.2 or 0.22 μm), the drug was diluted with physiological saline and intravenously administered within 60 minutes.
Study NCT04394078 — intervention group
Intervention type: OTHER
Intervention: Online survey
Description: Volunteer individuals enrolled the study after approval an online informed consent form. Sociodemographic data of the participants recorded as an online survey. Then, patient reported outcomes were used to assess depression (Zung depression Scale) and quality of life (WHO Qualiy of Life - Bref version).
Study NCT04034056 — intervention group
Intervention type: DRUG
Intervention: Obinutuzumab
Description: Induction phase: 1000 milligram (mg) intravenously (IV) on Day 1, 8, 15 of Cycle 1 an Day 1 of Cycles 2-6 or 2-8. Maintenance phase: 1000 mg IV every 2 months for 2 years or until disease progression (whatever occurs earlier).
Study NCT01263223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: Administered orally
Study NCT01263223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study NCT03234049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Checklist
Description: The Alberta Children's Hospital Trauma Checklist was developed by the ACH Resuscitation Council Trauma Committee in response to a quality assurance review of high-acuity trauma activations. It is a cognitive aid and focuses in particular on pre-arrival preparation and a pre-departure review prior to patient transfer to diagnostic imaging or the operating room.
Study NCT01636258 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management
Description: Every other week
Study NCT04278833 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Triamcinolone or Betamethasone
Description: Image guided intra-articular, peri-tendinous, or intra-bursal corticosteroid injection
Study NCT04278833 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: Image guided intra-articular, peri-tendinous, or intra-bursal corticosteroid injection